ImmunoGen has entered into a multi-target license and option partnership with privately-held ImmunoBiochem to advance novel and first-in-class antibody-drug conjugates against unique cancer targets, the companies announced Monday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,